Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.51 |
| ▸ | F2 | P00734 | 2/20 | 0.49 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.48 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4198227 | 1.00 | OPRM1 (0.51) | OPRM1OPRD1OPRK1F2NPFFR1 | |
| SCHEMBL4016026 | 1.00 | OPRM1 (0.51) | OPRM1OPRD1OPRK1F2NPFFR1 | |
| SCHEMBL23256152 | 1.00 | OPRM1 (0.51) | OPRM1OPRD1OPRK1F2NPFFR1 | |
| SCHEMBL5056855 | 1.00 | OPRM1 (0.51) | OPRM1OPRD1OPRK1F2NPFFR1 | |
| Hydrochloric Acid SCHEMBL6681663 | 0.99 | OPRM1 (0.50) | OPRM1OPRD1OPRK1F2NPFFR1 | |
| SCHEMBL6601122 | 0.93 | OPRM1 (0.53) | OPRM1OPRD1NPFFR1NPFFR2 | |
| SCHEMBL4940699 | 0.91 | OPRM1 (0.49) | OPRM1OPRD1OPRK1F2NPFFR1 | |
| SCHEMBL8586979 | 0.91 | OPRM1 (0.49) | OPRM1OPRD1OPRK1F2NPFFR1 | |
| SCHEMBL2849826 | 0.91 | OPRM1 (0.49) | OPRM1OPRD1OPRK1F2NPFFR1 | |
| SCHEMBL4709438 | 0.91 | OPRM1 (0.49) | OPRM1OPRD1OPRK1F2NPFFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10357448-B2 | Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-07-23 | — | — | US | claimed |
| US-20180042841-A1 | Echogenic Vehicle for Clinical Delivery of Plasminogen Activator and Other Fibrin-Binding Therapeutics to Thrombi | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-02-15 | — | — | US | claimed |
| US-9814672-B2 | Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-11-14 | — | — | US | claimed |
| CN-102458555-B | With the non-implantable medical equipment of the embedded nano granule coating containing therapeutic agent | CONCEPT MEDICAL INC. (US) | 2015-12-16 | — | — | CN | claimed |
| CN-102481196-B | Transferring nano-encapsulated drug through medical devices | ENVISION SCIENT PRIVATE LTD | 2015-05-27 | — | — | CN | claimed |
| CN-102481196-A | Re-establishment of blood flow in blocked human arteries by transferring nano-encapsulated drug through medical devices, designed for the same and releasing the nano- encapsulated drug in human artery with body ph | ENVISION SCIENT PRIVATE LTD | 2012-05-30 | — | — | CN | claimed |
| CN-102458555-A | Rejuvenating coronary artery by improving blood flow with the help of insertion of nano-balls (encapsulated nanoparticles) containing therapeutic agents by non implantable device for tissues and thereby providing in tissue release to address the requ | CONCEPT MEDICAL INC | 2012-05-16 | — | — | CN | claimed |
| US-20080305156-A1 | Echogenic Vehicle for Clinical Delivery of Plasminogen Activator and Other Fibrin-Binding Therapeutics to Thrombi | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-11 | — | — | US | claimed |
| WO-2001038560-A2 | ACTIVE ENZYME DETECTION USING IMMOBILIZED ENZYME INHIBITORS | AMERICAN RED CROSS (US) | 2001-05-31 | — | — | WO | claimed |
| US-5643580-A | Biocompatible coating, medical device using the same and methods | SURFACE GENESIS, INC. (US) | 1997-07-01 | — | — | US | claimed |
| EP-0237332-B1 | ASSAY FOR THROMBOSIS-RELATED MATERIALS | GENENTECH, INC. (US) | 1993-06-09 | — | — | EP | claimed |
| US-5096811-A | Tripeptide chloromethyl ketone enzyme inhibitor | GENENTECH, INC. (US) | 1992-03-17 | — | — | US | claimed |
| EP-0396692-A1 | A METHOD OF ASSAYING AN ENZYME AND KIT AND SUBSTANCES SUITABLE FOR THAT METHOD | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk onderzoek TNO (NL) | 1990-11-14 | — | — | EP | claimed |
| WO-1990005309-A1 | A METHOD OF ASSAYING AN ENZYME AND KIT AND SUBSTANCES SUITABLE FOR THAT METHOD | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 1990-05-17 | — | — | WO | claimed |
| EP-0237332-A1 | Assay for thrombosis-related materials | GENENTECH, INC. (US) | 1987-09-16 | — | — | EP | claimed |
| US-20250281503-A1 | DO3A-BASED ANTITHROMBOTIC AGENT OR HEMOLYTIC AGENT CONTAINING GADOLINIUM COMPLEX | ETNOVA THERAPEUTICS CORP. (KR) | 2025-09-11 | — | — | US | disclosed |
| EP-4031108-B1 | EXTRUDED DEPOT FORM FOR CONTROLLED ACTIVE SUBSTANCE RELEASE | AMW GMBH (DE) | 2025-04-02 | — | — | EP | disclosed |
| EP-0365597-A1 | IMPROVED PROCESSES FOR THE TREATMENT OF VASCULAR DISEASE. | GENENTECH INC (US) | 1990-05-02 | — | — | EP | disclosed |
| WO-1989000197-A1 | IMPROVED PROCESSES FOR THE TREATMENT OF VASCULAR DISEASE | GENENTECH, INC. (US) | 1989-01-12 | — | — | WO | disclosed |
| EP-0237332-A1 | Assay for thrombosis-related materials | GENENTECH, INC. (US) | 1987-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281503-A1 | DO3A-BASED ANTITHROMBOTIC AGENT OR HEMOLYTIC AGENT CONTAINING GADOLINIUM COMPLEX | SERPINC1, PRTN3, F13A1 | OPRM1 4421/4885OPRD1 3849/4885OPRK1 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.